Patent expands MEAI’s global intellectual property protection as Clearmind advances clinical development and commercialization plans

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application in South Korea covering compositions containing its proprietary compound, 5-methoxy-2-aminoindane (MEAI), for the treatment of depression.

This filing further strengthens Clearmind’s global intellectual property portfolio for MEAI, a novel, non-hallucinogenic neuroplastogen designed to modulate serotonin pathways, promote neuroplasticity, and alleviate depressive symptoms without the psychoactive effects associated with traditional psychedelics.

According to the World Health Organization, major depressive disorder affects more than 280 million people worldwide and remains one of the leading causes of disability, with limited innovative treatment options available.

Preclinical studies have demonstrated MEAI’s potential to enhance mood regulation and reduce anhedonia, offering a differentiated therapeutic approach for patients who do not respond to conventional antidepressants. This patent application further reinforces Clearmind’s robust IP portfolio, which now includes protections across multiple jurisdictions for MEAI’s applications in various mental health and addiction disorders.

“This patent filing marks another important milestone in expanding our IP protection and advancing MEAI as a novel, next-generation treatment for depression,” said Adi Zuloff-Shani, PhD, CEO of Clearmind Medicine. “As we continue to broaden our global footprint, we are also preparing for the next stages of clinical development and commercialization to potentially bring our non-hallucinogenic neuroplastogen therapies to patients worldwide.”